    Mayu Sris | Sarissa Capital Management LP | ZoomInfo.com      Mayu Sris - Insider Monkey                          Companies 0 See All     Hedge Funds 0 See All    Insiders 0 See All    Institutional Investors 0 See All   Click here to see all  results for  Sorry, no results has been found matching your query.                   Adblocker Detected    Dear Valued Visitor, We have noticed that you are using an ad blocker software.
    Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages. To view this article, you can disable your ad blocker and refresh this page or simply login. We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.       Home > Insider Trading > Mayu Sris
				> Profile    Mayu Sris    Profile Insider Purchases Insider Sales News      Affiliations  Other at Vivus Inc (VVUS), 2017-01-18 Director at Emmaus Life Sciences Inc. (NONE), 2014-07-21                Home Hedge Funds Markets Blog Authors About Us Contact Us Privacy Policy Terms of Use Site Map  All text and design is copyright ©2016 Koala Guide LLC. All rights reserved.             




















 



 Emmaus Life Sciences Appoints New Members To Board Of Directors 
         










    











 






 











 









Emmaus Life Sciences Appoints New Members To Board Of Directors

		  Duane Kurisu, Moni Miyashita, Phillip Satow and Mayu Sris Join Board as Independent Directors
		

May 22, 2014, 08:00 ET
		  		  						
						 from   Emmaus Life Sciences, Inc. 











 
















































 

 




















 


TORRANCE, Calif., May 22, 2014 /PRNewswire/ -- Emmaus Life Sciences, Inc., a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases, today announced the appointment of four new members to its Board of Directors:

Duane Kurisu, Chairman and CEO of Aio; 
Moni Miyashita, Senior Advisor with a global consulting firm and former IBM Vice President, Corporate Development; 
Phillip Satow, Chairman of the Board of JDS Therapeutics and co-Founder and former CEO of JDS Pharmaceuticals; and 
Mayu Sris, Founding Partner and Managing Director of Sarissa Capital Management. 
Mr. Kurisu, Ms. Miyashita, Mr. Satow and Mr. Sris join Emmaus' independent directors, Tracey Doi, Chief Financial Officer of Toyota Motor Sales, U.S.A., and Dr. Henry McKinnell, Chairman of the Board of Moody's Corporation and former Chairman and CEO of Pfizer.
"We welcome these four outstanding new board members at an exciting time for our company, having recently completed our phase 3 clinical trial for the treatment of sickle cell disease," said Dr. Yutaka Niihara, M.D., M.P.H., Founder and CEO of Emmaus Life Sciences. "Collectively, their depth of experience in business strategy, management and the pharmaceutical industry will strengthen our company as we position it for the next phase of growth." 
"We are delighted that Duane, Moni, Phil and Mayu have joined the board," said Dr. Henry McKinnell, Chairman of the Board of Emmaus Life Sciences.  "I look forward to working with them to guide the company as it works to bring the first new, and potential widely-available, sickle cell disease treatment to patients in more than 20 years." 
Following is biographical information on the new Emmaus directors:
Mr. Kurisu is the Chairman, Chief Executive Officer and owner of Aio Group, a holding company for consumer brands focused on Hawaii and the Pacific in the areas of media, sports and food. He also is the owner, director and Vice President of Nutricopia, Inc., a nutraceuticals company; owner, Manager and Chief Executive Officer of PacificBasin Communications, LLC, a publishing company; and owner and a manager of K&F 1984 LLC, a real estate company. Mr. Kurisu has served on the board of Central Pacific Financial Corp., a bank holding company, since January 25, 2012 and also served as a director of Central Pacific Financial Corp. from September 2004 to May 2008. Mr. Kurisu also is the owner, director and Vice President of Hawaii Winter Baseball, Inc., a professional baseball league in Hawaii. He holds B.B.A. and M.B.A. degrees from the University of Hawaii.
Ms. Miyashita is an independent advisor on mergers and acquisitions at a global consulting firm. She previously held a more than 30 year career at IBM, where she served as Vice President, Corporate Development, including 15 years in executive M&A roles as Vice President, M&A Strategy and Investments; Managing Director of M&A Integration; and Director of Corporate Development Asia Pacific, headquartered in Tokyo. Ms. Miyashita serves on the Board of Trustees of the Children's Hospital of Philadelphia; the Executive Advisory Board of the University of Denver's Daniels School of Business; the International Executive Advisory Council of The Navigators; and the Board of Directors of the US-Japan Council. Ms. Miyashita holds a B.S. degree in Marketing from the University of Colorado, Leeds School of Business, and a M.B.A. from the University of Denver, Daniels School of Business.
Mr. Satow is currently Chairman of the Board of Directors of JDS Therapeutics, LLC, which markets proprietary healthcare products to physicians, healthcare-delivery networks and other healthcare professionals. He was co-founder, Chairman and CEO of JDS Pharmaceuticals, LLC, a specialty pharmaceutical company focused in the fields of psychiatric and women's health treatments. JDS Pharmaceuticals was sold to Noven Pharmaceuticals, Inc. in 2008. Prior to founding JDS Pharmaceuticals, Mr. Satow served as Executive Vice President of Forest Laboratories, Inc., President of Forest Pharmaceuticals, Inc., and as a member of Forest's Board of Directors. Prior to joining Forest, Mr. Satow served as Vice President and General Manager of the Wallace Laboratories Division of Carter–Wallace, Inc. In addition, he has held executive positions at Pfizer, including Director of Marketing with Pfizer Laboratories and Vice President of Pfizer Europe. Mr. Satow holds a B.A. degree from Columbia College and an M.A. degree in Economics from Georgetown University.
Mr. Sris is a Founding Partner and Managing Director of Sarissa Capital Management LP, a hedge-fund firm. He most recently served as an Investment Analyst at Icahn Capital, an investment company, from 2005 to 2010 and as a consultant in 2011, where he contributed to all aspects of the activist investing process with the goal of proactively creating substantial value. Prior to Icahn Capital, Mr. Sris served as a consultant at Bain & Company, a management consulting firm, from 2002 to 2005, working with both corporate and private equity clients.  Previously, he served as an investment banker at Wasserstein Perella & Company, an investment bank, where he advised technology clients on M&A transactions. In addition, from 2006 to 2010, Mr. Sris was a member of the Board of Directors of publicly traded Viskase Companies, Inc.  Mr. Sris received his A.B. degree from Brown University.
About Emmaus Life Sciences, Inc.
Emmaus Life Sciences is dedicated to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases.
For more information, please visit www.emmauslifesciences.com.
Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and potential commercialization of pharmaceutical products. Such forward-looking statements, including, but not limited to, helping position Emmaus for the next phase of the company's growth and working to bring a sickle cell disease treatment to patients, are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. Additional risks and uncertainties are described in reports filed by Emmaus Life Sciences, Inc. with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2013 and Quarterly Report on Form 10-Q for the period ended March 31, 2014. Emmaus is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
Contacts:
Media: Lori Teranishi for Emmaus Life Sciences, Inc.415-981-1964lteranishi@iqprinc.com 
Investors:Matt Sheldon |Roger Pondel for Emmaus Life Sciences, Inc.310-279-5980investor@pondel.com 
 SOURCE  Emmaus Life Sciences, Inc.  

RELATED LINKS
http://www.emmausmedical.com



  

 View Table Fullscreen 




  View Table Fullscreen 





Journalists and Bloggers
The news you need, when you need it.
 
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.
LEARN MORE




 

 
 



















































  











Nov 24, 2014, 08:43 ET
Preview: Emmaus Life Sciences To Present Phase 3 Sickle Cell Disease Trial Data At 56th American Society Of Hematology Annual Meeting













Mar 20, 2014, 08:00 ET
Preview: Emmaus Life Sciences anuncia resultados principales positivos de su ensayo clínico de Fase 3 para la enfermedad de células falciformes






My News


  Release contains wide tables.	  View fullscreen.






 Read More





Feb 01, 2017, 08:00 ET
Emmaus Life Sciences, Inc. to Present at Los Angeles Biomedical...








Feb 01, 2017, 08:00 ET
Emmaus Life Sciences, Inc. Receives Notice of Allowance for...








Feb 01, 2017, 08:00 ET
Emmaus Life Sciences, Inc. Receives Notice of Allowance for U.S....











Looking to send a news release with PR Newswire?
Take advantage of the world's leading distribution platform.
Sign up to get started
Request more information
Have an account? Log In

 















Search











Searching for your content...









Advanced Search












































 


 


Insider Trading - Sris Mayu - Form 4 SEC Filings












Home |
Archives |
Products |
About |
Contact |
FAQ |



New User?
Sign Up | 
Sign In









Form 4 Filings


Insider Buys


Significant Buys


Penny StocksInsider Buying


Insider Sales




Insider Buy Sell Ratios


Stock Options


Insider TradingStock Screener


Insider TradingGraph View


Insider Watch





Sec Filings Insider Trading - Sris Mayu





Select Time period: 
1 Month
2 Months
3 Months
6 Months
1 Year
2 Years
3 Years
4 Years
All Data
 

     



google

   



yahoo!



Send this page to:  

Blog
  



Digg

  



Reddit

  



Facebook

  



Stumble

  



del.icio.us








Enter Stock Ticker Symbol or Cik:




Cik Lookup...






Search By Company or Insider Name:







"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch ==>>

What is insider trading>>



Email a friend >>...







Historical filings delayed by 6 months. New user?
Sign Up for real time data.
Existing user?
Sign In

Stock options: Exercise, Award, Grant, Conversion



TransactionDate
ReportedDate
ExercisableExpiration
Company
Symnbol
InsiderRelationship
SharesTraded
ConversionPrice
SharesOwned
Filing




2016-12-15Exercise
2016-12-195:16 pm
N/AN/A
Vivus Inc
VVUS
Sris MayuDirector
1,389
$0
29,168(Direct)
View


2016-12-15Disposition
2016-12-195:16 pm
N/AN/A
Vivus Inc
VVUS
Sris MayuDirector
347
$1.38
29,168(Direct)
View


2016-12-15Exercise
2016-12-195:16 pm
N/AN/A
Vivus Inc
VVUS
Sris MayuDirector
1,389
$0
29,168(Direct)
View


2016-11-15Exercise
2016-11-164:56 pm
N/AN/A
Vivus Inc
VVUS
Sris MayuDirector
1,389
$0
30,557(Direct)
View


2016-11-15Disposition
2016-11-164:56 pm
N/AN/A
Vivus Inc
VVUS
Sris MayuDirector
347
$1.1
30,557(Direct)
View


2016-11-15Exercise
2016-11-164:56 pm
N/AN/A
Vivus Inc
VVUS
Sris MayuDirector
1,389
$0
30,557(Direct)
View


2016-10-15Exercise
2016-10-184:45 pm
N/AN/A
Vivus Inc
VVUS
Sris MayuDirector
1,389
$0
31,946(Direct)
View


2016-10-15Disposition
2016-10-184:45 pm
N/AN/A
Vivus Inc
VVUS
Sris MayuDirector
347
$1.06
31,946(Direct)
View


2016-10-15Exercise
2016-10-184:45 pm
N/AN/A
Vivus Inc
VVUS
Sris MayuDirector
1,389
$0
31,946(Direct)
View


2016-09-15Exercise
2016-09-195:02 pm
N/AN/A
Vivus Inc
VVUS
Sris MayuDirector
1,389
$0
33,335(Direct)
View


2016-09-15Disposition
2016-09-195:02 pm
N/AN/A
Vivus Inc
VVUS
Sris MayuDirector
347
$1.06
33,335(Direct)
View


2016-09-15Exercise
2016-09-195:02 pm
N/AN/A
Vivus Inc
VVUS
Sris MayuDirector
1,389
$0
33,335(Direct)
View


2016-08-15Exercise
2016-08-174:55 pm
N/AN/A
Vivus Inc
VVUS
Sris MayuDirector
1,389
$0
34,724(Direct)
View


2016-08-15Disposition
2016-08-174:55 pm
N/AN/A
Vivus Inc
VVUS
Sris MayuDirector
347
$1.09
34,724(Direct)
View


2016-08-15Exercise
2016-08-174:55 pm
N/AN/A
Vivus Inc
VVUS
Sris MayuDirector
1,389
$0
34,724(Direct)
View


2016-07-15Exercise
2016-07-195:27 pm
N/AN/A
Vivus Inc
VVUS
Sris MayuDirector
1,389
$0
36,113(Direct)
View


2016-07-15Disposition
2016-07-195:27 pm
N/AN/A
Vivus Inc
VVUS
Sris MayuDirector
347
$1.15
36,113(Direct)
View


2016-07-15Exercise
2016-07-195:27 pm
N/AN/A
Vivus Inc
VVUS
Sris MayuDirector
1,389
$0
36,113(Direct)
View


2016-06-15Exercise
2016-06-174:23 pm
N/AN/A
Vivus Inc
VVUS
Sris MayuDirector
1,388
$0
37,502(Direct)
View


2016-06-15Disposition
2016-06-174:23 pm
N/AN/A
Vivus Inc
VVUS
Sris MayuDirector
347
$1.19
37,502(Direct)
View


2016-06-15Exercise
2016-06-174:23 pm
N/AN/A
Vivus Inc
VVUS
Sris MayuDirector
1,388
$0
37,502(Direct)
View


2016-05-15Exercise
2016-05-174:37 pm
N/AN/A
Vivus Inc
VVUS
Sris MayuDirector
11,110
$0
38,890(Direct)
View


2016-05-15Disposition
2016-05-174:37 pm
N/AN/A
Vivus Inc
VVUS
Sris MayuDirector
2,777
$1.16
38,890(Direct)
View


2016-05-15Exercise
2016-05-174:37 pm
N/AN/A
Vivus Inc
VVUS
Sris MayuDirector
11,110
$0
38,890(Direct)
View


2016-04-29Option Award
2016-05-039:13 pm
N/AN/A
Vivus Inc
VVUS
Sris MayuDirector
50,000
$0
50,000(Direct)
View


2015-10-30Option Award
2015-11-035:29 pm
N/A2022-10-30
Vivus Inc
VVUS
Sris MayuDirector
25,000
$1.26
25,000(Direct)
View









    © 2005-2017 SecForm4.Com All rights reserved.
    Archives:
    2017 2016 2015 2014 2013 2012 ... 
    Fri, 28 Jul 2017 16:13:20 -0500
  

    SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
    SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC).
Terms of Use |
    Privacy Statement |
  










Mayu  Sris - CEO, founder, businessman - profile

















directorpedia.net - List of CEOs, founders, board members and company directors











Mayu  Sris
Check out list of companies and businesses related to Mayu  Sris. Find out Mayu  Sris address and contact details. View other people related to Mayu  Sris - coworkers, colleagues, companions, etc.
Address:   

20725 S. WESTERN AVE. SUITE 136 TORRANCE 90501 CA




Companies related to Mayu  Sris
CIKCompany NamePositionCompany Address0000881524VIVUS INCDirector 900 E. HAMILTON AVENUE SUITE 550 CAMPBELL 950080001420031EMMAUS LIFE SCIENCES, INC.Director 21250 HAWTHORNE BLVD. SUITE 800 TORRANCE 90503




Mayu  Sris on the Web
Persons related to Mayu  Sris - VIVUS INCNamePositionCityMICHAEL J  ASTRUEDirector MOUNTAIN VIEWRolf E.  BassBERLINJON C  BIRO10% Owner HOUSTONJ MARTIN  CARROLLDirector MOUNTAIN VIEWJ MARTIN  CARROLLDirector MOUNTAIN VIEWCHARLES J  CASAMENTODirector MOUNTAIN VIEWCHARLES J  CASAMENTODirector MOUNTAIN VIEWWang  ChangjinVP, Business Development MOUNTAIN VIEWSamuel F  ColinDirector MOUNTAIN VIEWWesley  DayVP, Clinical Development MOUNTAIN VIEWWesley  DayVP, Clinical Development MOUNTAIN VIEWWesley  DayVP, Clinical Development MOUNTAIN VIEWAlexander J  DennerDirector GREENWICHALEXANDER J  DENNERDirector GREENWICHJOHN W  DIETRICHVice President, R & D JOHN W  DIETRICHVice President, R & D MOUNTAIN VIEWFirst BioMed Management Associates LLCNEW YORKMANHATTAN CO  FIRSTNEW YORKSeth H.Z.  FischerChief Executive Officer SAN DIEGOSeth H.Z.  FischerChief Executive Officer MOUNTAIN VIEWLori  ForrestVP, Operations & General Mgr. LAKEWOODNEIL  GESUNDHEITVP, Chief Medical Officer NEIL  GESUNDHEITMOUNTAIN VIEWJACOB PIETER KASTELEIN  JOHANNESDirector MOUNTAIN VIEWMELVIN L  KEATINGLIVINGSTONTHOMAS BRAXTON  KINGSALT LAKE CITYConan  LaughlinBOSTONConan  LaughlinBOSTONConan  LaughlinBOSTONMARK B  LOGANDirector MARK B  LOGANDirector MOUNTAIN VIEWMARK B  LOGANDirector MOUNTAIN VIEWERNEST  MARIODirector MOUNTAIN VIEWGUY P  MARSHVP, Operations & General Mgr. GUY P  MARSHVP, Operations and General Mgr MOUNTAIN VIEWGUY P  MARSHVP, Operations and General Mgr MOUNTAIN VIEWGUY P  MARSHVP, US Operations & GM MOUNTAIN VIEWMICHAEL /NY/  MILLERChief Commercial Officer MOUNTAIN VIEWMICHAEL PATRICK  MILLERMOUNTAIN VIEWJohann Noor  MohamedMOUNTAIN VIEWTIMOTHY E  MORRISVP, Finance and CFO UNION CITYTIMOTHY E  MORRISVP, Finance and CFO MOUNTAIN VIEWTIMOTHY E  MORRISVP, Finance and CFO MOUNTAIN VIEWJAMES R  NICKELVice President, Clinical JAMES R  NICKELMOUNTAIN VIEWTERRY  NIDAVP, Worldwide Marketing/ TERRY  NIDAVP, Worldwide Marketing/ MOUNTAIN VIEWNORTH TIDE CAPITAL, LLC10% Owner BOSTONNorth Tide Capital Master, LPBOSTONNorth Tide Capital Master, LPBOSTONDavid Y  NortonDirector EAST BRUNSWICKDavid Y  NortonPRINCETONDavid Y  NortonDirector MOUNTAIN VIEWDavid Y  NortonMOUNTAIN VIEWMark K  OkiChief Financial Officer & CAO MOUNTAIN VIEWLee  PerryVP & Chief Accounting Officer MOUNTAIN VIEWVIRGIL A  PLACEChairman & CSO VIRGIL A  PLACEChief Scientific Officer MOUNTAIN VIEWVIRGIL A  PLACEChief Scientific Officer MOUNTAIN VIEWJorge MD  PlutzkyDirector MOUNTAIN VIEWJorge MD  PlutzkyDirector MOUNTAIN VIEWEric W  RobertsDirector NEW YORKMARIO M  ROSATIDirector PALO ALTOMARIO M  ROSATISecretary PALO ALTOMARIO M  ROSATIDirector PALO ALTOHERM  ROSENMANDirector SAN DIEGOHERM  ROSENMANSAN DIEGOHERM  ROSENMANDirector MOUNTAIN VIEWSvai S  SanfordChief Financial Officer MOUNTAIN VIEWSvai S  SanfordInterim CFO MOUNTAIN VIEWSvai S  SanfordCFO & Chief Accounting Officer MOUNTAIN VIEWSarissa Capital Domestic Fund LPGREENWICHSarissa Capital Domestic Fund LPGREENWICHSarissa Capital Management LPGREENWICHSarissa Capital Management LPGREENWICHSarissa Capital Offshore Master Fund LPGREENWICHSarissa Capital Offshore Master Fund LPGREENWICHAllan  ShawDirector NEW YORKLINDA M DAIRIKI  SHORTLIFFEDirector PALO ALTOLINDA M DAIRIKI  SHORTLIFFEDirector MOUNTAIN VIEWJohn L  SlebirSVP, Business Development & GC MOUNTAIN VIEWJohn L  SlebirSVP & General Counsel MOUNTAIN VIEWJohn L  SlebirSVP, Business Development & GC MOUNTAIN VIEWMayu  SrisDirector TORRANCEGRAHAM  STRACHANDirector GRAHAM  STRACHANDirector MOUNTAIN VIEWLARRY J  STRAUSSVice President, Finance & CFO PETER Y  TAMSenior VP, Commerical & PETER Y  TAMPresident MOUNTAIN VIEWSantosh T  VargheseChief Medical Officer MOUNTAIN VIEWRICHARD W  WALLISERLELAND F  WILSONPresident & CEO MENLO PARKLELAND F  WILSONChief Executive Officer MOUNTAIN VIEWROBERT N  WILSONDirector MOUNTAIN VIEWROBERT N  WILSONMOUNTAIN VIEWROBERT N  WILSONDirector MOUNTAIN VIEWCAROL  ZOLTOWSKIVice President, Regulatory CAROL  ZOLTOWSKIMOUNTAIN VIEWAnthony P.  ZookChief Executive Officer MOUNTAIN VIEWPersons related to Mayu  Sris - EMMAUS LIFE SCIENCES, INC.NamePositionCityAFH Holding & Advisory, LLCBEVERLY HILLSOsborne Jr.  AlfredTorranceHeshmatpour  AmirBEVERLY HILLSHeshmatpour  AmirTorranceTIMOTHY  BRASELGREENWOOD VILLAGETIMOTHY  BRASELVice President AURORAMAURICE J  DEWALDLOS ANGELESMAURICE J  DEWALDDirector LOS ANGELESMAURICE J  DEWALDDirector TORRANCEMAURICE J  DEWALDDirector TORRANCETracey  DoiDirector TORRANCETracey  DoiDirector TORRANCEGriffin Ventures Ltd.BEVERLY HILLSMcKinnell  HenryTorranceMcKinnell  HenryTorranceAmir F  HeshmatpourDirector BEVERLY HILLSAmir F  HeshmatpourDirector BEVERLY HILLSAmir F  HeshmatpourDirector BEVERLY HILLSAmir F  HeshmatpourDirector BEVERLY HILLSAmir F  HeshmatpourPresident and Secretary BEVERLY HILLSZwicker  IanTorranceKuwahara  JonTorranceKPM Tech Co. Ltd.GYEONG-GI-DODUANE K  KURISUDirector TORRANCEJon  KuwaharaDirector TORRANCETran  LanTorranceTran  LanTorranceTran  LanTorranceSangho Steve  LeeTORRANCEWILLIS C  LEEVice Chairman & COO TORRANCEWILLIS C  LEEDirector TORRANCEWILLIS C  LEETORRANCEWILLIS C  LEEChief Operating Officer TORRANCEPeter  LudlumChief Business Officer TORRANCEPeter  LudlumEVP and CFO TORRANCEOsato  MasaharuTorranceDeWald  MauriceTorranceDeWald  MauriceTorranceHENRY A  MCKINNELLDirector TORRANCEHENRY A  MCKINNELLDirector TORRANCEAkiko Moni  MiyashitaDirector TORRANCEYASUSHI  NAGASAKISenior VP, Finance TORRANCEYASUSHI  NAGASAKISenior VP, Finance TORRANCESoomi  NiiharaTORRANCEYutaka  NiiharaChairman and CEO TORRANCEYutaka  NiiharaPresident and CEO TORRANCEMasaharu  OsatoDirector TORRANCEALFRED E  OSBORNE JRLOS ANGELESALFRED E  OSBORNE JRDirector LOS ANGELESLudlum  PeterTorranceLudlum  PeterTorrancePHILLIP M  SATOWTORRANCEPHILLIP M  SATOWDirector TORRANCEMayu  SrisDirector TORRANCEBrasel  TimothyBEVERLY HILLSDoi  TraceyTorranceDoi  TraceyTorranceDoi  TraceyTorranceLan T.  TranChief Administrative Officer TORRANCELan T.  TranChief Administrative Officer TORRANCELan T.  TranChief Administrative Officer TORRANCESTEVE B  WARNECKETORRANCELee  WillisTorranceLee  WillisTorranceLee  WillisTorranceDOUGLAS  WILMORETORRANCENagasaki  YasushiTorranceNagasaki  YasushiTorranceNagasaki  YasushiTorranceNiihara  YutakaTorranceNiihara  YutakaTorranceNiihara  YutakaTorranceIan Harvey  ZwickerDirector TORRANCE












 














VVUS SEC Filings Report for 09/20/2016 | News Quantified




























×






-9.4339622641499E-05
-9.4339622641499E-05
-0.00367924528301888
0.0214150943396226
0.00943396226415095
0.00943396226415095
0.0187735849056604
0.0188679245283019





SECreport







Form 4 VIVUS INC For: Sep 15 Filed by: Sris Mayu



VIVUS (VVUS) 
More Company Research
Source: SEC EDGAR




Last vivus earnings: 5/3 04:10 pm
Check Earnings Report














IMPACT SNAPSHOT
EVENT TIME: 
VVUS






Last Price






Price Change








Price Change %








Volume Shares






Max Up






Max Down





Volume Ratio
%









Performance comparison
Updated 






EVENT DAY

Stock performance from the time of news release until the following 4pm ET market close



LAST PRICE AT NEWS EVENT




SINCE EVENT
Multi-day stock performance from the time of the news release






EVENT DAY

Stock performance from the time of news release until the following 4pm ET market close



LAST PRICE AT NEWS EVENT




SINCE EVENT
Multi-day stock performance from the time of the news release







LAST PRICE










VWAP








High: 

MAX UP


High: 





Low: 

MAX DOWN


Low: 








%


POST NEWS RANGE

%








PRICE CHANGE













PRICE CHANGE PERCENTAGE
















S&P 500 (SPX)










%





VOLUME RATIO

%











VOLUME (SHARES)










TICKS













AVG SHARES PER TRADE
















+

9.43%



VVUS's stock demonstrates remarkable incline of +9.43% from 1.06-share to 1.16-share since news hit the wires



via News Quantified

CLICK TO SHARE:












EVENT DAY


Event Day Chart will not be displayed beyond 90-day period of the event




PERFORMANCE SINCE EVENT





TIME AND VELOCITY ANALYSIS








Be the first to know
Opt in for alerts from News Quantifed


SIGN UP TODAY












In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know
exactly what the average effect will be on a particular stock.


Subscribe
Stay in the know news, product updates and promotions.


Subscribe



Contact us

20715 N Pima Rd #F108  Scottsdale, AZ 85255


Email: info@newsquantified.com



Support

Disclaimers
Privacy Policy
Terms of Use
Contact Us



Information

Home
About Us
Services

Analyst Actions Elite
Institutions
Market Impact Report

Contact
Blog



Latest Posts

How to Find Big Gains on Positive Earnings Reports


One Monday, Three Great Trades


These Three Companies Are Set To Crush Wall Street’s Expectations


Three Diverse Plays from the 7-17 Trading Session


Using High Volume News to Find Big Gains: Three Pharma Plays




Copyright Ⓒ News Quanitifed LLC.
1.0.3








In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.


Latest Posts

How to Find Big Gains on Positive Earnings Reports


One Monday, Three Great Trades


These Three Companies Are Set To Crush Wall Street’s Expectations


Three Diverse Plays from the 7-17 Trading Session


Using High Volume News to Find Big Gains: Three Pharma Plays



Information

Home
About Us
Services

Analyst Actions Elite
Institutions
Market Impact Report

Contact
Blog



Support

Disclaimers
Privacy Policy
Terms of Use
Contact Us



Contact us

20715 N Pima Rd #F108  Scottsdale, AZ 85255


Email: info@newsquantified.com



Subscribe
Stay in the know news, product updates and promotions.


Subscribe




Copyright Ⓒ News Quanitifed LLC.
1.0.3




















Sris Mayu - Vivus Insider Transactions | TipRanks   





Go ProLogin / Sign Up Follow✓Get Real Time TransactionsInsider DetailsSris MayuVivus (VVUS)Director Not RankedSris Mayu's PerformanceSris Mayu has not reported any informative transactions and therefore cannot be ranked.How are Insiders Ranked? Sris Mayu's Trading Historybased on Form 4 Follow✓Get Real Time TransactionsCompany NameInsider PositionHolding ValueLast TransactionLast Transaction  AmountLast Transaction DateVVUSVivusDirector-Uninformative Buy$2,916Jan 18, 2017Sris Mayu has not reported any informative transactions for VVUS, therefore, performance cannot be measured. Track Record DateTransactionAmountNo. of SharesPrice per ShareProfitForm 4 Jan 18, 2017 Uninformative Buy $3K 9,722 $1.17 N/A  Dec 19, 2016 Uninformative Buy $479 1,389 $1.27 N/A  Nov 16, 2016 Uninformative Buy $382 1,389 $1.12 N/A Show MoreSee All Insider Trading from Today >You May Also LikeMeet our Smart Portfolio. See what top analysts say about your stocks.Get a breakdown of the different strategies based on detected insider trading activity.Find the best performing Analyst in each sector. Follow them so you never miss a recommendation.Related LinksHow can I benefit from Insider Trading? >See the Top 25 Corporate Insiders >Go to Hot Stocks by Insiders >Find which stocks Insiders traded today >Become a TipRanks MemberGet the best Investing Tips & Hacks straight to your emailFree MembershipSubmitInsider Trading Daily NewsletterProfessional day-trading strategy based on predictive insider transactionsAnnual Return: +85.42%Learn More >Powered by



































SRIS MAYU Insider Insider Trades - NASDAQ.com



























































Hot Topics:
ETFs |
Smart Portfolio |
Currencies |
Online Broker Center















Search






















Home > 
    Quotes > 
    Ownership & Insider Trades > 
    Individual Insiders






Insider Trades of SRIS MAYU





Click on the column header to resort ascending (▲) or descending (▼).



Individual Insider Trades



Company


Relation


Last Date ▼


Type


Tran


OwnerType


Shares Traded


Last Price


Shares Held



VIVUS INC
Other
01/16/2017
Form 4
Disposition (Non Open Market)
direct
2,083
1.2
22,918


VIVUS INC
Other
01/15/2017
Form 4
Disposition (Non Open Market)
direct
347
1.2
16,668


VIVUS INC
Director
12/15/2016
Form 4
Disposition (Non Open Market)
direct
347
1.38
15,626


VIVUS INC
Director
11/15/2016
Form 4
Disposition (Non Open Market)
direct
347
1.1
14,584


VIVUS INC
Director
10/15/2016
Form 4
Disposition (Non Open Market)
direct
347
1.06
13,542


VIVUS INC
Director
09/15/2016
Form 4
Disposition (Non Open Market)
direct
347
1.06
12,500


VIVUS INC
Director
08/15/2016
Form 4
Disposition (Non Open Market)
direct
347
1.09
11,458


VIVUS INC
Director
07/15/2016
Form 4
Disposition (Non Open Market)
direct
347
1.15
10,416


VIVUS INC
Director
06/15/2016
Form 4
Disposition (Non Open Market)
direct
347
1.19
9,374


VIVUS INC
Director
05/15/2016
Form 4
Disposition (Non Open Market)
direct
2,777
1.16
8,333















Highest Rated Articles of Last Week



Shareholders Approve Major Structural Change to Top Performing...
Yatra Attains Leadership Position in Corporate Travel With the...
Mitel To Acquire ShoreTel - Quick Facts
Miller Heiman Group Selects CallidusCloud Datahug for Pipeline...
Tractor Supply Company Reports Second Quarter Results





View All Highest Rated































Most Rated Stocks of Last Week
Rated stocks for NASDAQ, NYSE and AMEX

Symbol  /  Ratings Consensus

AAPL

86% bullish
                    of
                    2913
                    ratings
Rate It


FB

76% bullish
                    of
                    1328
                    ratings
Rate It


TSLA

78% bullish
                    of
                    588
                    ratings
Rate It


MSFT

84% bullish
                    of
                    649
                    ratings
Rate It


GOOG

91% bullish
                    of
                    128
                    ratings
Rate It


JPM

70% bullish
                    of
                    88
                    ratings
Rate It


GM

68% bullish
                    of
                    80
                    ratings
Rate It


BAC

75% bullish
                    of
                    475
                    ratings
Rate It


NFLX

68% bullish
                    of
                    325
                    ratings
Rate It


INTC

83% bullish
                    of
                    266
                    ratings
Rate It


More Most Rated Stocks



























CLOSEX

Edit Favorites

Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.






Update

Clear List







CLOSEX
Customize your NASDAQ.com experience
Background Color Selector

Select the background color of your choice:





 Black
							





 Slate Gray
							






 Light Gray
							





 Gray Blue
							






Quote Search

Select a default target page for your quote search:



						 Real-Time

						 After Hours

						 Pre-Market
 News
					


						 Flash Quote

						 Summary Quote

						 Interactive Charts

						 Default Setting




					Please note that once you make your selection, it will apply to all future visits to NASDAQ.com.
					If, at any time, you are interested in reverting to our default settings, please select Default Setting above.
					
					If you have any questions or encounter any issues in changing your default settings, please email isfeedback@nasdaq.com.
				





CLOSEX
Please confirm your selection:

					You have selected to change your default setting for the Quote Search. This will now be your default target page;
					unless you change your configuration again, or you delete your
					cookies. Are you sure you want to change your settings?


YES
NO













CLOSEX


Please disable your ad blocker (or update your settings to ensure that javascript and cookies are enabled), so that we can continue to provide you with the first-rate market news and data you've come to expect from us.





CLOSEX



































